Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Autopsy
  • Brentuximab Vedotin
  • Fatal Outcome
  • Female
  • Hodgkin Disease / complications
  • Hodgkin Disease / drug therapy
  • Humans
  • Immunoconjugates / adverse effects*
  • Immunoconjugates / therapeutic use
  • Lymphoma, Large-Cell, Anaplastic / complications
  • Lymphoma, Large-Cell, Anaplastic / drug therapy
  • Male
  • Middle Aged
  • Pancreatitis / chemically induced*
  • Pancreatitis / pathology
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • Brentuximab Vedotin